# A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Study · id `cardio:ct-nct01217073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01217073](<https://clinicaltrials.gov/study/NCT01217073>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01217073

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 685 participants.

## Technical summary

Registry record NCT01217073. Randomized; triple masking; primary purpose treatment. Start 2010-10-08 (actual); primary completion 2012-01-03 (actual). Results posted on 2015-10-29.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 685 participants (enrolled count; ClinicalTrials.gov record NCT01217073, source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)
- Started: 2010-10-08 (actual) (ClinicalTrials.gov record NCT01217073, source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2012-01-03 (actual) (ClinicalTrials.gov record NCT01217073, source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)
- Completion: 2013-04-01 (actual) (ClinicalTrials.gov record NCT01217073, source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2015-10-29 (ClinicalTrials.gov record NCT01217073, source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01217073-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Placebo to omarigliptin
- Intervention (Drug): Pioglitazone
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo to metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes (`cardio:pubmed-26310692`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cd87ac84e84d4353d798017b1813ff3c88e089488ea888d9cd5fb8fb37041ddb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
